Sanofi Walks Away From Plavix Provincial Tender In China
This article was originally published in PharmAsia News
Despite expected pricing pressure, the depth of cuts from China’s closely watched provincial tenders for newly added essential drugs still bring out surprises, and even walkaways, as reference pricing remains a threat.
You may also be interested in...
A major European business group in China is encouraged by recent signals of further policy reforms, but says in a new report it would like to see further progress on drug and device tenders, the lifting of indirect competition restrictions, and full implementation of the central push for a level playing field for foreign firms.
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.